Table 2

Study completion status

SAD stage
No. (%) of patients	Placebo (n=5)	0.3 mg/kg IV (n=4)	1.0 mg/kg IV (n=4)	3.0 mg/kg IV (n=4)	3.0 mg/kg SC (n=4)	10.0 mg/kg IV (n=4)	All active (n=20)
Study completion status
Subjects completed study	3 (60)	3 (75)	4 (100)	2 (50)	3 (75)	3 (75)	15 (75)
Subjects discontinued early	2 (40)	1 (25)	0 (0)	2 (50)	1 (25)	1 (25)	5 (25)
Reasons for study termination
Physician decision to withdraw subjects from study	2 (40)	1 (25)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)
Subjects' decision to withdraw	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	1 (20)	2 (10)
Adverse event	0 (0)	0 (0)	0 (0)	2 (50)	0 (0)	0 (0)	2 (10)

MD stage
No. (%) of patients	Placebo (n=5)	0.5 mg/kg SC (n=4)	1.5 mg/kg SC (n=5)	3.0 mg/kg SC (n=4)	4.0 mg/kg IV (n=5)	All Active (n=18)
Study completion status
Subjects completed study	4 (80)	3 (75)	2 (40)	2 (50)	4 (80)	11 (61)
Subjects discontinued early	1 (20)	1 (25)	3 (60)	2 (50)	1 (20)	7 (39)
Reasons for study termination
Physician decision to withdraw subjects from study	0 (0)	0 (0)	1 (20)	1 (25)	0 (0)	2 (11)
Subjects' decision to withdraw	1 (20)	0 (0)	1 (20)	1 (25)	0 (0)	2 (11)
Adverse event	0 (0)	1 (25)	1 (20)	0 (0)	1 (20)	3 (17)

IV, intravenous; MD, multiple dose; SAD, single ascending dose; SC, subcutaneous.